OASMIA PHARMACE/ADR stock opened at $1.84 on Friday. OASMIA PHARMACE/ADR has a 12 month low of $1.20 and a 12 month high of $5.70.
OASMIA PHARMACE/ADR (NASDAQ:OASM) last released its earnings results on Friday, March 1st. The company reported ($0.04) EPS for the quarter. OASMIA PHARMACE/ADR had a negative return on equity of 42.16% and a negative net margin of 6,025.94%. The company had revenue of $0.16 million during the quarter.
About OASMIA PHARMACE/ADR
Oasmia Pharmaceutical AB (publ) develops, manufactures, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden. It focuses on manufacturing formulations and drug-delivery systems based on cytostatics. The company's approved products include Paclical/Apealea, a water-soluble formulation of XR17 and paclitaxel to treat cancers, such as lung, breast, and ovarian cancer; and Paccal Vet, a formulation for the treatment of squamous cell carcinoma and mammary carcinoma in dogs.
See Also: Trading based on a resistance level
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for OASMIA PHARMACE/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OASMIA PHARMACE/ADR and related companies with MarketBeat.com's FREE daily email newsletter.